News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TipRanks Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Satellos Bioscience reported a Q2 2026 net loss of $11.7 million, or $0.56 per share, missing analyst estimates due to significantly increased R&D spending on its Phase 2 DMD clinical trials. Despite the widening loss, the company's cash reserves rose to $61.8 million, providing …
Satellos Bioscience Inc. announced its Q2 2026 financial results, reporting a strong cash position of $61.8 million and progress in its clinical trials for SAT-3247, a drug candidate for Duchenne muscular dystrophy (DMD). The company highlighted favorable safety data from the TRAILHEAD adult DMD …
Satellos reported its second quarter 2026 financial results, including a net loss of $11.7 million, and provided updates on its clinical progress for SAT-3247 in Duchenne muscular dystrophy (DMD). The company highlighted stable strength and reduced muscle fat in a Phase 2 adult DMD …
Satellos Bioscience reported increased net losses in the first half of 2026 due to higher R&D and G&A expenses, driven by advancing its Duchenne muscular dystrophy (DMD) clinical programs, SAT-3247. Despite widening losses, the company significantly strengthened its cash position to $61.8 million through …
Satellos Bioscience Inc. (TSX:MSCL) experienced a 4.52% stock decline due to investor caution surrounding clinical-stage biotechnology companies, which face inherent development and funding risks. The company, focused on regenerative medicine for muscle disorders, is valued based on its clinical progress, technology validation, and potential …
Sharemaestro market context Price above Trend Line 52 weeks +89.0%This article provides a basic overview of Satellos Bioscience Inc. (NEO:MSCL) on TradingView, focusing on its financial data and market performance. It indicates that no trades have occurred, suggesting limited market activity or a market closure. The page structure points to a detailed financial …
This article details the shareholder structure of Satellos Bioscience Ord Shs (MSLE), providing a breakdown of major shareholders and institutional holdings. It lists the proportion of shares held by entities like Bloom Burton & Co. Inc., Franklin Advisers, Inc., and Empery Asset Management, L.P., …
This page on TradingView provides financial information for Satellos Bioscience Inc (LSX:A4211W), including an overview of its financials, statements, statistics, dividends, earnings, and segments. It specifically focuses on revenue breakdown by source and country. The content is primarily a navigation hub to various financial …
Franklin Berger, an Independent Director at Satellos Bioscience Inc. (TSE:MSCL), recently bought CA$117k worth of stock, increasing his holdings by 1.9%. This adds to a larger previous purchase of CA$339k earlier in the year at a higher price, indicating continued confidence in the company. …
Sharemaestro market context Price above Trend Line 52 weeks +89.0%Search by ticker symbol or company name and select a result to open its chart.